tiprankstipranks
Kymera Therapeutics, Inc. (KYMR)
NASDAQ:KYMR
US Market
KYMR
Kymera Therapeutics
RESEARCH TOOLSreports
Want to see KYMR full AI Analyst Report?

Kymera Therapeutics (KYMR) Stock Forecast & Price Target

444 Followers
See the Price Targets and Ratings of:

KYMR Analyst Ratings

Strong Buy
17Ratings
Strong Buy
15 Buy
2 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Kymera
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KYMR Stock 12 Month Forecast

Average Price Target

$130.07
▲(17.63% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Kymera Therapeutics in the last 3 months. The average price target is $130.07 with a high forecast of $155.00 and a low forecast of $115.00. The average price target represents a 17.63% change from the last price of $110.57.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"39":"$39","156":"$156","68.25":"$68.3","97.5":"$97.5","126.75":"$126.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":155,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$155.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":130.06666666666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$130.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$115.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[39,68.25,97.5,126.75,156],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,114.2,117.33846153846154,120.47692307692309,123.61538461538461,126.75384615384615,129.8923076923077,133.03076923076924,136.16923076923078,139.30769230769232,142.44615384615383,145.58461538461538,148.72307692307692,151.86153846153846,{"y":155,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,114.2,115.42051282051283,116.64102564102565,117.86153846153846,119.08205128205128,120.3025641025641,121.52307692307693,122.74358974358974,123.96410256410256,125.18461538461538,126.40512820512821,127.62564102564102,128.84615384615384,{"y":130.06666666666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,114.2,114.26153846153846,114.32307692307693,114.38461538461539,114.44615384615385,114.50769230769231,114.56923076923077,114.63076923076923,114.6923076923077,114.75384615384615,114.81538461538462,114.87692307692308,114.93846153846154,{"y":115,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.69,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.66,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.86,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.81,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.62,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.1,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.93,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.71,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.47,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$155.00Average Price Target$130.07Lowest Price Target$115.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Deutsche Bank Analyst forecast on KYMR
David Hoang
Deutsche Bank
Deutsche Bank
$120
Hold
8.53%
Upside
Initiated
07/29/26
Kymera Therapeutics initiated with a Hold at Deutsche BankKymera Therapeutics initiated with a Hold at Deutsche Bank
Guggenheim Analyst forecast on KYMR
Bradley Canino
Guggenheim
Guggenheim
$125→$135
Buy
22.09%
Upside
Reiterated
07/28/26
KBIO’s KT-579 IRF5 Degrader Drives Buy Rating as Analyst Lifts Price Target to $135 on Lupus Upside Potential
Mizuho Securities Analyst forecast on KYMR
Joseph Catanzaro
Mizuho Securities
Mizuho Securities
$120→$140
Buy
26.62%
Upside
Reiterated
07/16/26
Kymera Therapeutics price target raised to $140 from $120 at MizuhoKymera Therapeutics price target raised to $140 from $120 at Mizuho
Piper Sandler Analyst forecast on KYMR
Biren Amin
Piper Sandler
Piper Sandler
$140
Buy
26.62%
Upside
Reiterated
07/16/26
Analysts Conflicted on These Healthcare Names: aTyr Pharma (NASDAQ: ATYR), Kymera Therapeutics (NASDAQ: KYMR) and Cannara Biotech (Other OTC: LOVFF)
RBC Capital Analyst forecast on KYMR
Brian Abrahams
RBC Capital
RBC Capital
$106→$115
Hold
4.01%
Upside
Downgraded
07/13/26
Kymera Therapeutics downgraded to Sector Perform from Outperform at RBC CapitalKymera Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
Bank of America Securities Analyst forecast on KYMR
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$125
Buy
13.05%
Upside
Reiterated
06/30/26
Kymera Therapeutics: Accelerated KT-621 Development, $6B Peak Sales Potential, and Raised Price Target to $125 Support Buy Rating
Truist Financial Analyst forecast on KYMR
Srikripa Devarakonda
Truist Financial
Truist Financial
$116→$136
Buy
23.00%
Upside
Assigned
06/29/26
Kymera Therapeutics price target raised to $136 from $116 at TruistKymera Therapeutics price target raised to $136 from $116 at Truist
B. Riley Securities Analyst forecast on KYMR
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$117→$155
Buy
40.18%
Upside
Assigned
06/29/26
B. Riley Securities Remains a Buy on Kymera Therapeutics (KYMR)
Wells Fargo Analyst forecast on KYMR
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$116
Buy
4.91%
Upside
Reiterated
06/26/26
Wells Fargo Keeps Their Buy Rating on Kymera Therapeutics (KYMR)
Canaccord Genuity Analyst forecast on KYMR
Edward Nash
Canaccord Genuity
Canaccord Genuity
$106→$129
Buy
16.67%
Upside
Reiterated
06/26/26
Kymera Therapeutics price target raised to $129 from $106 at CanaccordKymera Therapeutics price target raised to $129 from $106 at Canaccord
Citi Analyst forecast on KYMR
Geoff Meacham
Citi
Citi
$120
Buy
8.53%
Upside
Reiterated
06/25/26
Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (NASDAQ: ABCL) and Kymera Therapeutics (NASDAQ: KYMR)
BTIG Analyst forecast on KYMR
Jeet Mukherjee
BTIG
BTIG
$134
Buy
21.19%
Upside
Reiterated
06/25/26
Kymera: Accelerated Atopic Dermatitis Timeline and KT-621 Potential Drive Jeet Mukherjee’s Buy Rating
J.P. Morgan Analyst forecast on KYMR
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/25/26
Analysts Are Bullish on Top Healthcare Stocks: Alpha Teknova (TKNO), Kymera Therapeutics (KYMR)
Morgan Stanley Analyst forecast on KYMR
Judah Frommer
Morgan Stanley
Morgan Stanley
$123→$119
Buy
7.62%
Upside
Reiterated
06/25/26
Analysts Offer Insights on Healthcare Companies: Anteris Technologies Global Corp. (NASDAQ: AVR) and Kymera Therapeutics (NASDAQ: KYMR)
Barclays Analyst forecast on KYMR
Eliana Merle
Barclays
Barclays
$133
Buy
20.29%
Upside
Reiterated
06/22/26
Kymera Therapeutics (KYMR) Receives a Buy from Barclays
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Deutsche Bank Analyst forecast on KYMR
David Hoang
Deutsche Bank
Deutsche Bank
$120
Hold
8.53%
Upside
Initiated
07/29/26
Kymera Therapeutics initiated with a Hold at Deutsche BankKymera Therapeutics initiated with a Hold at Deutsche Bank
Guggenheim Analyst forecast on KYMR
Bradley Canino
Guggenheim
Guggenheim
$125→$135
Buy
22.09%
Upside
Reiterated
07/28/26
KBIO’s KT-579 IRF5 Degrader Drives Buy Rating as Analyst Lifts Price Target to $135 on Lupus Upside Potential
Mizuho Securities Analyst forecast on KYMR
Joseph Catanzaro
Mizuho Securities
Mizuho Securities
$120→$140
Buy
26.62%
Upside
Reiterated
07/16/26
Kymera Therapeutics price target raised to $140 from $120 at MizuhoKymera Therapeutics price target raised to $140 from $120 at Mizuho
Piper Sandler Analyst forecast on KYMR
Biren Amin
Piper Sandler
Piper Sandler
$140
Buy
26.62%
Upside
Reiterated
07/16/26
Analysts Conflicted on These Healthcare Names: aTyr Pharma (NASDAQ: ATYR), Kymera Therapeutics (NASDAQ: KYMR) and Cannara Biotech (Other OTC: LOVFF)
RBC Capital Analyst forecast on KYMR
Brian Abrahams
RBC Capital
RBC Capital
$106→$115
Hold
4.01%
Upside
Downgraded
07/13/26
Kymera Therapeutics downgraded to Sector Perform from Outperform at RBC CapitalKymera Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
Bank of America Securities Analyst forecast on KYMR
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$125
Buy
13.05%
Upside
Reiterated
06/30/26
Kymera Therapeutics: Accelerated KT-621 Development, $6B Peak Sales Potential, and Raised Price Target to $125 Support Buy Rating
Truist Financial Analyst forecast on KYMR
Srikripa Devarakonda
Truist Financial
Truist Financial
$116→$136
Buy
23.00%
Upside
Assigned
06/29/26
Kymera Therapeutics price target raised to $136 from $116 at TruistKymera Therapeutics price target raised to $136 from $116 at Truist
B. Riley Securities Analyst forecast on KYMR
Mayank Mamtani
B. Riley Securities
B. Riley Securities
$117→$155
Buy
40.18%
Upside
Assigned
06/29/26
B. Riley Securities Remains a Buy on Kymera Therapeutics (KYMR)
Wells Fargo Analyst forecast on KYMR
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$116
Buy
4.91%
Upside
Reiterated
06/26/26
Wells Fargo Keeps Their Buy Rating on Kymera Therapeutics (KYMR)
Canaccord Genuity Analyst forecast on KYMR
Edward Nash
Canaccord Genuity
Canaccord Genuity
$106→$129
Buy
16.67%
Upside
Reiterated
06/26/26
Kymera Therapeutics price target raised to $129 from $106 at CanaccordKymera Therapeutics price target raised to $129 from $106 at Canaccord
Citi Analyst forecast on KYMR
Geoff Meacham
Citi
Citi
$120
Buy
8.53%
Upside
Reiterated
06/25/26
Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (NASDAQ: ABCL) and Kymera Therapeutics (NASDAQ: KYMR)
BTIG Analyst forecast on KYMR
Jeet Mukherjee
BTIG
BTIG
$134
Buy
21.19%
Upside
Reiterated
06/25/26
Kymera: Accelerated Atopic Dermatitis Timeline and KT-621 Potential Drive Jeet Mukherjee’s Buy Rating
J.P. Morgan Analyst forecast on KYMR
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/25/26
Analysts Are Bullish on Top Healthcare Stocks: Alpha Teknova (TKNO), Kymera Therapeutics (KYMR)
Morgan Stanley Analyst forecast on KYMR
Judah Frommer
Morgan Stanley
Morgan Stanley
$123→$119
Buy
7.62%
Upside
Reiterated
06/25/26
Analysts Offer Insights on Healthcare Companies: Anteris Technologies Global Corp. (NASDAQ: AVR) and Kymera Therapeutics (NASDAQ: KYMR)
Barclays Analyst forecast on KYMR
Eliana Merle
Barclays
Barclays
$133
Buy
20.29%
Upside
Reiterated
06/22/26
Kymera Therapeutics (KYMR) Receives a Buy from Barclays
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kymera Therapeutics

3 Months
Eliana MerleBarclays
Success Rate
7/10 ratings generated profit
70%
Average Return
+17.71%
Copying Eliana Merle's trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +17.71% per trade.
1 Year
Faisal KhurshidJefferies
Success Rate
11/12 ratings generated profit
92%
Average Return
+107.39%
Copying Faisal Khurshid's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +107.39% per trade.
2 Years
Faisal KhurshidJefferies
Success Rate
12/12 ratings generated profit
100%
Average Return
+163.11%
Copying Faisal Khurshid's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +163.11% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KYMR Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
7
3
4
5
3
Buy
17
18
16
22
22
Hold
1
0
0
0
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
21
20
27
27
In the current month, KYMR has received 25 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. KYMR average Analyst price target in the past 3 months is 130.07.
Each month's total comprises the sum of three months' worth of ratings.

KYMR Financial Forecast

KYMR Earnings Forecast

Next quarter’s earnings estimate for KYMR is -$0.71 with a range of -$1.42 to -$0.27. The previous quarter’s EPS was -$0.71. KYMR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year KYMR has Performed in-line its overall industry.
Next quarter’s earnings estimate for KYMR is -$0.71 with a range of -$1.42 to -$0.27. The previous quarter’s EPS was -$0.71. KYMR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year KYMR has Performed in-line its overall industry.

KYMR Sales Forecast

Next quarter’s sales forecast for KYMR is $32.78M with a range of $2.00M to $65.00M. The previous quarter’s sales results were $34.37M. KYMR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.23% of the time in the same period. In the last calendar year KYMR has Performed in-line its overall industry.
Next quarter’s sales forecast for KYMR is $32.78M with a range of $2.00M to $65.00M. The previous quarter’s sales results were $34.37M. KYMR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.23% of the time in the same period. In the last calendar year KYMR has Performed in-line its overall industry.

KYMR Stock Forecast FAQ

What is KYMR’s average 12-month price target, according to analysts?
Based on analyst ratings, Kymera Therapeutics, Inc.’s 12-month average price target is 130.07.
    What is KYMR’s upside potential, based on the analysts’ average price target?
    Kymera Therapeutics, Inc. has 17.63% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is KYMR a Buy, Sell or Hold?
          Kymera Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 15 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Kymera Therapeutics, Inc.’s price target?
            The average price target for Kymera Therapeutics, Inc. is 130.07. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $155.00 ,the lowest forecast is $115.00. The average price target represents 17.63% Increase from the current price of $110.57.
              What do analysts say about Kymera Therapeutics, Inc.?
              Kymera Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of KYMR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.